SCHEMBL10273940

SCHEMBL10273940

Cc1ccc2c(C(=O)Nc3cc(F)c(C)cc3C)csc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ NPC1 O15118 4/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ MAPT P10636 4/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ TP53 P04637 2/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ MCOLN3 Q8TDD5 1/20 0.38
▸ F10 P00742 1/20 0.38
▸ GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10273141 0.90 RAB9A (0.46) RAB9ALMNANPC1KMT2AMEN1
SCHEMBL14772101 0.87 SMN1; SMN2 (0.37) RAB9AHSD17B10LMNATSHRNPC1
SCHEMBL91550 0.80 MAPT (0.41) LMNASMN1; SMN2MAPTALDH1A1TP53
SCHEMBL92608 0.80 RAB9A (0.43) RAB9ALMNANPC1KMT2AMEN1
SCHEMBL91671 0.80 HDAC3 (0.54) RAB9AHSD17B10LMNANPC1KMT2A
SCHEMBL10273942 0.80 MAOB (0.45) RAB9AHSD17B10LMNATSHRNPC1
SCHEMBL91650 0.76 SMN1; SMN2 (0.49) RAB9AHSD17B10LMNANPC1KMT2A
SCHEMBL91667 0.76 MAPT (0.55) RAB9AHSD17B10LMNANPC1KMT2A
SCHEMBL10285850 0.76 MAOB (0.58) RAB9AHSD17B10LMNANPC1KMT2A
SCHEMBL10273941 0.76 MAPT (0.51) RAB9ANPC1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 RAB9A 1503/4885HSD17B10 651/4885LMNA 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback